Home / Market News / $ALNY
fiscal.ai Corporate Catalyst Impact 55/100 ● negative

Citigroup Adjusts Alnylam Pharmaceuticals Price Target

Nov 10, 2026, 12:34 PM UTC · Primary ticker $ALNY

Citigroup has lowered its price target for Alnylam Pharmaceuticals from $320 to $250, indicating a revised financial outlook for the biopharmaceutical company. This adjustment suggests a less optimistic view from the analyst firm, which could influence investor sentiment and potentially lead to short-term price volatility for Alnylam shares.

Citigroup's decision to reduce Alnylam Pharmaceuticals' price target from $320 to $250 signals a more cautious stance from the analyst firm regarding the company's future valuation. This change is significant for Alnylam as analyst price targets often influence investor perception and trading decisions. While not a direct recommendation, a lowered price target can lead to negative sentiment and potential selling pressure in the short term. For traders, this presents a potential opportunity to re-evaluate their positions in ALNY, considering the revised outlook from a major financial institution. The long-term implications depend on the underlying reasons for Citigroup's adjustment, which are not detailed in this filing but could relate to clinical trial outcomes, market competition, or broader economic factors affecting the biopharmaceutical sector.

$ALNY negative Price target reduction
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.